Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
COLUMN
Technology Provides Opportunities for Medical Device Companies
Philip Carrigan Will 2016 be the year that medical device companies cash in and navigate terrains that are increasingly integrated with new technology? In a recent press conference held by the Japan Medical Imaging and Radiological Systems Industries Association (JIRA),…
To read the full story
COLUMN
- More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry
May 29, 2026
- The Patient North Star: How Gilead Japan Redefined Innovation
April 8, 2026
- Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
March 27, 2026
- The Strategic MSL: Beyond Data Delivery, It’s About Impact
February 19, 2026
- AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential
January 27, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…